Last update 20 Mar 2025

Lifileucel

Overview

Basic Info

Drug Type
TIL therapy
Synonyms
Autologous Tcell therapy Iovance Biotherapeutics, Autologoustumourinfiltratinglymphocytes, Contego
+ [2]
Target-
Action-
Mechanism
Immunologic cytotoxicity, T lymphocyte replacements
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (16 Feb 2024),
RegulationFast Track (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Priority Review (United States), Regenerative Medicine Advanced Therapy (United States), Accelerated Approval (United States)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Melanoma
United States
16 Feb 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic melanomaNDA/BLA
European Union
28 Jun 2024
Unresectable MelanomaNDA/BLA
European Union
28 Jun 2024
Advanced Endometrial CarcinomaPhase 2
United States
29 Oct 2024
Uterine Cervical CancerPhase 2
United States
21 Mar 2022
Ewing SarcomaPhase 1
United States
28 Mar 2024
Relapsed Solid NeoplasmPhase 1
United States
28 Mar 2024
RhabdomyosarcomaPhase 1
United States
28 Mar 2024
Dedifferentiated LiposarcomaPhase 1
United States
01 Nov 2022
Malignant Fibrous HistiocytomaPhase 1
United States
01 Nov 2022
Uveal MelanomaPhase 1
United States
01 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
160
(ipacbkruoq) = nlqhtirema hlzsjmkzub (dmudxztyuf, 24.1 - 39.4)
Positive
16 Feb 2024
(prior anti-PD-(L)1 therapy)
(ipacbkruoq) = lwytwjyrvx hlzsjmkzub (dmudxztyuf, 21.1 - 43.4)
Phase 2
153
(vwwotaakjw) = jkosvnucxj jyuxaljtsq (ovrouhoegc )
Positive
07 Dec 2023
Phase 2
15
(njockdkroy) = qmcjscxgdf msyxedjjka (ncjxxfkzcs, 21 - 79)
Positive
21 Oct 2023
Phase 2
28
(zfpmyygzpy) = qxksgeztig xvfedbptyy (frrjyrrpfq )
-
02 Jun 2022
(zfpmyygzpy) = wehnbnnrpy xvfedbptyy (frrjyrrpfq )
Phase 2
66
(zlfavplzmo) = wlfahbqutk dutzweeppc (yfpvnsttbk, 25 - 49)
Positive
20 Aug 2021
Phase 2
55
(dbwdjndbkl) = dlqliavayt vjlypsmbcb (ndanznzuhk )
Positive
26 May 2019
Phase 1/2
Melanoma
tumor infiltrating lymphocytes
-
(Tumor Infiltrating Lymphocytes (TILs))
pbarfjwbcs(hhljkmbnvu) = toxicities associated with high-dose IL-2 classically administered together with TILs are severe and recent data have questioned its use mfbxzeguja (hoglsxujcv )
Positive
12 Mar 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free